Grifols vs Zoetis
GRFS and ZTS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRFS and ZTS compare
Grifols grew revenue faster over the last twelve months (4.3% versus 1.5% for Zoetis).
Zoetis keeps more of each dollar of sales as profit, with a net margin of 27.5% compared with 5.3% at Grifols.
Zoetis pays a dividend yielding 2.6%; Grifols does not pay one.
Zoetis scores higher on the StockData Score (17 against 9 for Grifols), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRFS | ZTS |
|---|---|---|
| Size and price | ||
| Market cap | – | $32.9B |
| Share price | $8.10 | $79.72 |
| Change, 1 year | −13.7% | −44.6% |
| Change, 5 years | −33.7% | −63.2% |
| Beta (5Y) | 0.91 | 0.78 |
| Employees | 1,613 | 15K |
| StockData Score | ||
| Total score | 9 | 17 (better) |
| Valuation score | 0 | 5 (better) |
| Growth score | 2 | 2 |
| Performance score | 4 | 5 (better) |
| Health score | 3 | 3 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | – | 13.1× |
| P/S | – | 3.5× |
| P/B | – | 10.5× |
| EV/EBITDA | – | 10.1× |
| P/FCF | – | 14.2× |
| PEG | – | 1.28 |
| FCF yield | – | 7.0% |
| Fair value | – | $152.11 |
| Margin of safety | – | 47.6% |
| Growth | ||
| Revenue growth (TTM) | 4.3% (better) | 1.5% |
| Revenue growth, 5Y average | 7.1% | 7.2% (better) |
| Net income growth (TTM) | 156% (better) | 0.96% |
| EPS growth (TTM) | 157% (better) | 5.6% |
| EPS growth, 5Y average | −8.1% | 12.0% (better) |
| Profitability | ||
| Gross margin | 38.0% | 71.5% (better) |
| Operating margin | 16.5% | – |
| Net margin | 5.3% | 27.5% (better) |
| FCF margin | 10.4% | 24.3% (better) |
| Return on equity | 7.2% | 64.4% (better) |
| Return on invested capital | 14.6% | – |
| Financial health | ||
| Debt / equity | 0.41 (better) | 2.87 |
| Net debt / EBITDA | 0.79 (better) | 1.85 |
| Interest coverage | 2.0× | – |
| Current ratio | 2.51 | 3.08 (better) |
| Altman Z-score | – | 3.99 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 2.6% |
| Payout ratio | 31.8% | – |
| Years of dividend growth | – | 13 |
| Dividend growth, 5Y average | – | 19.0% |
| Buyback yield | – | 11.1% |
| Shareholder yield | – | 13.7% |
| Ownership | ||
| Held by institutions | 20.8% | 96.1% |
| Held by insiders | 0.00% | 0.08% |
| Insider net buying, 12 months | – | −$1.7M |
| Superinvestors holding | – | 3 |
| Short interest, % of float | – | 4.5% |
Go deeper
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
- ZTS stock overview
- ZTS income statement
- ZTS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.